TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25846577
Drug: Add-on exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add-on exenatide twice daily
Study: 21864718
Drug: Culturally appropriate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally appropriate, group-based behavioral and social support intervention including 16 weekly group sessions and 8 weeks of telephone maintenance counseling.
Study: 21864718
Drug: Minimal intervention
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal intervention control group receiving 16 weekly health education mailings.
Study: 17555707
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral group program for spouses of stroke patients (15 bi-monthly 1.5 hour sessions)
Study: 15776275
Drug: Carbamazepine 200
Normalized name: carbamazepine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 200 mg/day for 6 days
Study: 11919661
Drug: Buprenorphine 2
Normalized name: buprenorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 2 mg daily
Study: 11919661
Drug: Buprenorphine 4
Normalized name: buprenorphine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 4 mg/placebo on alternating days
Study: 11919661
Drug: Buprenorphine 32
Normalized name: BUPRENORPHINE 32MG/0.64ML SA INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 32 mg/placebo on alternating days
Study: 11919661
Drug: High-dose buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose buprenorphine (regardless of schedule)
Study: 835509
Drug: Iron-fortified grain
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified grain products daily for 6 to 8 months
Study: 835509
Drug: Daily ferrous
Normalized name: Ferrous Fumarate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily ferrous sulfate administration for those with hemoglobin levels below 13 g/dl
Study: 2430506
Drug: Pneumococcal vaccine
Normalized name: PNEUMOCOCCAL VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal vaccine combined with oral penicillin-V (twice daily)
Study: 2430506
Drug: Pneumococcal vaccine
Normalized name: PNEUMOCOCCAL VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal vaccine combined with benzathine penicillin (intramuscularly every 4 weeks)
Study: 24745701
Drug: Grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass pollen sublingual immunotherapy
Study: 23444750
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation with antioxidant agents containing alpha lipoic acid (ALA) plus calcium and vitamin D3 (n = 25)
Study: 16218969
Drug: Intra-oral injection
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-oral injection of ketorolac (30 mg in 1 mL)
Study: 11872034
Drug: Apomorphine SL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine SL (2 mg for 2 weeks, then 3 mg for 2 weeks, and finally 4 mg for the remaining 4 weeks)
Study: 9989366
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg od)
Study: 7787438
Drug: Adjunctive antithyroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antithyroid drugs (ATD) in a form of block‐replacement regimen of methimazole (MMI) plus L‐T4 for 6 months
Study: 7787438
Drug: Radioiodine (RAI)
Normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine (RAI) therapy alone
Study: 2370643
Drug: Dilevalol (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (acute and chronic treatment)
Study: 31991296
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (1500 mg, three times per day) for 3 months
Study: 17081532
Drug: Postoperative triptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative triptorelin treatment
Study: 16251373
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise (weekly exercise class consisting of light aerobic exercise, muscle strengthening and stretching for 6 months)
Study: 1918559
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy (CT)
Study: 1918559
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (CO)
Study: 25800041
Drug: Adjuvant intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant intra-arterial chemotherapy (IAC) and concomitant radiotherapy (RT)
Study: 22492368
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL red orange juice/d
Study: 22492368
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL placebo/d
Study: 2039045
Drug: Preoperative 0.03%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative 0.03% flurbiprofen every 30 minutes for four doses
Study: 6981162
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of two double-strength trimethoprim-sulfamethoxazole (TMP-SMZ) tablets (320 mg of TMP and 1,600 mg of SMZ)
Study: 6981162
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy of one double-strength tablet (160 mg of TMP and 800 mg of SMZ) twice a day for 10 days
Study: 26329939
Drug: Topical Tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Tacrolimus 0.03% twice daily for three weeks
Study: 17313301
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g L-carnitine L-tartrate
Study: 17313301
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g L-carnitine L-tartrate
Study: 17313301
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g L-carnitine L-tartrate (control)
Study: 17055209
Drug: Madopar (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madopar (200 mg levodopa and 50 mg benserazide)
Study: 15687727
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole (injection) 40 mg once daily for 1 week, followed by oral esomeprazole 40 mg once daily for 3 weeks
Study: 15687727
Drug: Intravenous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esomeprazole (infusion) 40 mg once daily for 1 week, followed by oral esomeprazole 40 mg once daily for 3 weeks
Study: 15687727
Drug: Oral esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral esomeprazole 40 mg once daily for 4 weeks
Study: 8233728
Drug: High caloric
Normalized name: high caloric supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: High caloric supplement (500 kcal/d)
Study: 8233728
Drug: Low caloric
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low caloric supplement (140 kcal/d)
Study: 3898976
Drug: Pivampicillin 700
Normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin 700 mg twice daily for 6 days
Study: 25794603
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dabrafenib and trametinib
Study: 15226337
Drug: Conventionally fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally fractionated cranial radiation therapy (CFX)
Study: 15226337
Drug: Hyperfractionated cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionated cranial radiation therapy (HFX)
Study: 11477497
Drug: 4.2 g
Normalized name: CHLORINE 4.2 g in 100 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.2 g CLA/day
Study: 7822600
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral thermometry (CRAFTEMP)
Study: 7822600
Drug: Optimum oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimum oral thermometry (TERUMO WCT)
Study: 7822600
Drug: Routine rectal
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine rectal thermometry (TERUMO WCT)
Study: 7822600
Drug: Optimum rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimum rectal thermometry (TERUMO WCT)
Study: 3168766
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg dexamethasone
Study: 18071344
Drug: Habit-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habit-based intervention (n=69, with subgroups of n=33 for weekly weighing and n=36 for monthly weighing)
Study: 9346982
Drug: Three new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three new topical anesthetics (prilocaine-phenylephrine, tetracaine-phenylephrine, tetracaine-lidocaine-phenylephrine)
Study: 8478305
Drug: Dirithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirithromycin (500 mg orally once daily)
Study: 8478305
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg orally qds)
Study: 3006464
Drug: diatrizoate (ionic
Approvals — FDA: no, EMA: no, PMDA: no
Description: diatrizoate (ionic radiographic contrast agent)
Study: 3006464
Drug: iopamidol (nonionic
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopamidol (nonionic radiographic contrast agent)
Study: 30518693
Drug: Metformin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,500 mg) + Saline
Study: 30518693
Drug: Ex vivo
Normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex vivo Metformin
Study: 25562774
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care intervention (usual care plus pharmaceutical care)
Study: 18236371
Drug: prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone acetate 1 % eye drops 5 x /day, tapering off by one drop every month
Study: 16487668
Drug: Prison methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prison methadone treatment
Study: 14723479
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine patch therapy (n = 2)
Study: 14723479
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch therapy (n = 4)
Study: 20533241
Drug: GPLC (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPLC (4.5 g/day)
Study: 10630656
Drug: Age adjusted
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age adjusted warfarin loading protocol
Study: 10630656
Drug: Empirical dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical dosing
Study: 1666684
Drug: High-dose naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose naloxone (10 mg bolus plus 7 mg/hr)
Study: 6462107
Drug: Gentamicin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin alone (2 mg/kg IV)
Study: 6462107
Drug: Gentamicin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin with carbenicillin (2 g IV every 8 h for six doses)
Study: 6462107
Drug: Gentamicin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin with piperacillin (4 g IV every 12 h for four doses)
Study: 3840740
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (4 mg preservative-free morphine in 6 ml saline)
Study: 3840740
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anaesthetised without intrathecal morphine)
Study: 25772920
Drug: Re-wetting agent
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-wetting agent with 37% phosphoric acid etching
Study: 25772920
Drug: Re-wetting agent
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-wetting agent with Erbium: Yttrium aluminium garnet laser etching
Study: 16573545
Drug: Thymoglobulin induction,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin induction, rapamycin (RAPA), and immunonutrients (arginine and omega-3 fatty acids); Mycophenolate mofetil (MMF) started in standard doses and discontinued by 2 years; CsA given in reduced doses for either 4, 6, or 12 months.
Study: 10715225
Drug: Sorbitol 40
Normalized name: sorbitol 40 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol 40 g/day in candy
Study: 10715225
Drug: Olestra 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra 20 g/day in potato chips
Study: 10715225
Drug: Olestra 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra 40 g/day in potato chips
Study: 8268900
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (nitrendipine, possibly with a converting-enzyme inhibitor and a thiazide)
Study: 3082592
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg norethisterone acetate + 50 micrograms ethinyloestradiol (NA 1 + EE 50)
Study: 24397906
Drug: MenACWY-CRM plus
Normalized name: hydrocortisone Rectal Cream [Recort Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM plus routine vaccines
Study: 24220326
Drug: Routine vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine vaccines alone
Study: 18544424
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 270 microg/kg rFVIIa
Study: 18544424
Drug: On-demand treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand treatment schedules (multiple bolus doses of 90 to 120 microg/kg every 2 to 3 hours)
Study: 9013369
Drug: Codeine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (60 mg administered orally)
Study: 1568521
Drug: Intra-articular rifamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular rifamycin SV (525 mg/week) for 10 weeks
Study: 1568521
Drug: Auranofin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin (3 mg orally twice daily)
Study: 31763263
Drug: Nasya +
Normalized name: Hyaluronic acid (NASHA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasya + Oral Group
Study: 28371482
Drug: 1% brinzolamide/0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% brinzolamide/0.5% timolol fixed combination (BTFC)
Study: 28371482
Drug: 1% dorzolamide/0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% dorzolamide/0.5% timolol fixed combination (DTFC)
Study: 25265147
Drug: Remifentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (1 μg/kg) and thiopental sodium (4 mg/kg)
Study: 25265147
Drug: Thiopental sodium
Normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopental sodium (3 mg/kg, placebo)
Study: 21693655
Drug: Doxorubicin (60,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60, 75, or 90 mg/m²) and cyclophosphamide with paclitaxel
Study: 21693655
Drug: Doxorubicin (60,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60, 75, or 90 mg/m²) and cyclophosphamide without paclitaxel
Study: 12650957
Drug: mianserin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin (15 mg/day)
Study: 11019421
Drug: L-arginine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (15 g/day for 10 days)
Study: 3880810
Drug: Survival by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survival by treatment
Study: 3880810
Drug: Complications of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complications of therapy
Study: 23241505
Drug: IL-2 plus
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 plus LMI vaccine
Study: 9071621
Drug: Terbinafine 125
Normalized name: terbinafine 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 125 mg orally twice daily for 4 weeks (Group 1, ages 5-15)
Study: 9071621
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg orally twice daily for 4 weeks (Group 2, ages > 15)
Study: 7361797
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (1 g four times daily)
Study: 30550828
Drug: Tezepelumab 280
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tezepelumab 280 mg plus class 3 topical corticosteroids (TCS)
Study: 30550828
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus class 3 topical corticosteroids (TCS)
Study: 23336594
Drug: MYO 2
Normalized name: Nymyo 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYO 2 g plus folic acid 200 mg every day
Study: 23336594
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 200 mg every day
Study: 17347063
Drug: ZOL 5
Normalized name: danazol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZOL 5 mg
Study: 17347063
Drug: ALN 70
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN 70 mg
Study: 8373713
Drug: Zolpidem (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (5 and 10 mg) after seven nightly doses
Study: 8373713
Drug: Nightly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nightly administration of zolpidem
Study: 28027368
Drug: Friendship Bench
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Friendship Bench intervention (6 sessions of individual problem-solving therapy delivered by trained, supervised lay health workers plus an optional 6-session peer support program)
Study: 19631948
Drug: Fluoxetine 20mg
Normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 20mg and Venlafaxine 150mg
Study: 18586659
Drug: Telavancin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin 7.5 mg/kg
Study: 18586659
Drug: Telavancin 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin 15 mg/kg
Study: 16028436
Drug: 12-week physical
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week physical activity programme (30 min of brisk walking and a daily 11-min home-based programme)
Study: 12503699
Drug: Terbutaline inhaled
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline inhaled 10 min before mannitol
Study: 12503699
Drug: Terbutaline inhaled
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline inhaled 5 min after mannitol
Study: 12503699
Drug: Terbutaline inhaled
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline inhaled 10 min before the control for mannitol
Study: 10519734
Drug: Simvastatin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (mean dose 28.6 mg/day)
Study: 10519734
Drug: Cholestyramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (mean dose 19.3 g/day)
Study: 7734901
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 20 mg/kg
Study: 31286118
Drug: Glycine air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine air polishing (G)
Study: 28500784
Drug: DL‐PDT (Daylight
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL‐PDT (Daylight Photodynamic Therapy)
Study: 21075536
Drug: Octenidine-Gel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octenidine-Gel®
Study: 19776406
Drug: High-dose daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose daunorubicin (90 mg/m²) plus cytarabine (100 mg/m²)
Study: 19776406
Drug: Standard-dose daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose daunorubicin (45 mg/m²) plus cytarabine (100 mg/m²)
Study: 17598694
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of topiramate (25 mg)
Study: 17598694
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of topiramate (25 mg)
Study: 11303823
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily (OD) gentamicin dosing
Study: 11303823
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily (TD) gentamicin dosing
Study: 9600579
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg oral m-CPP
Study: 9600579
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg oral m-CPP (females only)
Study: 7992274
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with Elmedistraal
Study: 23618609
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine (SC group) with fentanyl
Study: 23618609
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine (SC group)
Study: 17219967
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of Triptorelin (3.75 mg) at 6-week intervals
Study: 17219967
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of Triptorelin (3.75 mg) at 4-week intervals
Study: 10793603
Drug: Quinaprilat 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinaprilat 0.02 mg kg‐1 (group A)
Study: 10793603
Drug: Quinaprilat 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinaprilat 0.04 mg kg‐1 (group B)
Study: 10793603
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (group C)
Study: 30642076
Drug: TNF-α inhibitors
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF-α inhibitors (TNFi)